Immunomedics, Inc. , a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that its patent application for "Internalizing anti-CD74 antibodies and methods of use" has been issued as U.S. patent no. 7,312,318.
CytoGenix, Inc. announced today it has received a Notice of Allowance for a patent on its Herpes composition from the United States Patent and Trademark Office. The allowed patent entitled, "Treatment of HSV-Related Pathologies Using ssDNA," claims both the composition of matter utilizing the company's single stranded DNA (ssDNA) expression vector technology and methods of treatment utilizing the therapeutic compound.
Australian Biotech Solagran Limited today announced it had been awarded the world's first patents protecting the use of plant polyprenols in the treatment of conditions involving physical, psychological and neurological degeneration.
DiObex, Inc., a privately held biotechnology company developing treatments for metabolic diseases, announced today that it has secured a critical patent from the U.S. Patent and Trademark Office for the use of very low dose glucagon, or DIO-901, in the prevention of insulin-induced hypoglycemia in diabetes patients. The patent grants DiObex exclusive rights to methods of reducing the risk of hypoglycemia in diabetes patients being treated with insulin by administering very low doses of glucagon
Nastech Pharmaceutical Company Inc. announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. patent application No. 10/976,942, entitled "Phage Displayed Trp Cage Ligands." The patent application has claims that relate to a novel, high-throughput method for identifying peptides which can bind to specific cell types.
No comments:
Post a Comment